Results 201 to 210 of about 35,844 (248)

Follow-on osteoporosis therapy after denosumab discontinuation among Medicare beneficiaries. [PDF]

Osteoporos Int
Sendhil SR, Cadarette SM, Aggarwal S, Oganisian A, Zullo AR, Berry SD, Adegboye MA, Hayes KN.   +7 more
europepmc   +1 more source

A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumors

Mingchuan Zhao, Xichun Hu, Panpan Zhuang, Aiping Zeng, Yan Yu, Zhendong Chen, Hongmei Sun, Weihua Yang, Lili Sheng, Peijian Peng, Jingfen Wang, Tienan Yi, Minghong Bi, Huaqiu Shi, Mingli Ni, Xiumei Dai, Chang-Lu Hu, Hongjie Xu, Dongqing Lv, Qingshan Li, Kaijian Lei, Xia Yuan, Ou Jiang, Xicheng Wang, Baihui Hu, Zhé Hóu, Zhaoping Su, Song Zheng, Ming Zhou, Changlin Dou   +29 more
openalex   +1 more source

Metachronous multicentric giant cell tumor of bone treated with denosumab and mega-prosthesis revision: a rare case report. [PDF]

Front Oncol
Lin H, Yang C, Zhu J, Yang C, Xu Z, Wu Z, Wang X, Wang W.   +7 more
europepmc   +1 more source

Pharmacokinetics and pharmacodynamics of the denosumab biosimilar FKS518 and reference denosumab in healthy subjects: the Lumiade-1 study. [PDF]

JBMR Plus
Dryja A, Cieślak M, Sobieraj P, Szeles P, de Souza ALS, Monnet J.   +5 more
europepmc   +1 more source

Efficacy of denosumab treatment for lung metastasis secondary to proximal humerus chondroblastoma [PDF]

Ramy Samargandi, Mathilde Bernard, Elodie Miquelestorena‐Standley, Louis‐Romée Le Nail   +3 more
openalex   +1 more source

Analysis of the efficacy and safety of denosumab in the treatment of patients with osteoporotic vertebral compression fractures after PVP. [PDF]

Sci Rep
Jiang Y, He B, Shang Q, Liu H, Chen W, Zhao W, Shen G, Ren H, Jiang X.   +8 more
europepmc   +1 more source

Mind the gap: adherence to denosumab dosing and cessation guidelines in Australian residential aged care [PDF]

M.W. O’Donnell, Johanna Westbrook, Bayzidur Rahman, Isabelle Meulenbroeks, Nasir Wabe, Ian Cameron D, Mark Morgan, Magdalena Z. Raban   +7 more
openalex   +1 more source

Genomic analysis unlocks the potential of denosumab as a targeted therapy for Crohn's disease. [PDF]

Sci Rep
Pranata R, Ratnasari N, Bayupurnama P, Indrarti F, Aulia N, Rahmawati H, Adikusuma W, Mugiyanto E, Irham LM, Gunarto C, Alya SS, Hadi VF, Sentosa GC, Wahyuningsih AT, Lin CF, Satria RD.   +15 more
europepmc   +1 more source

Efficacy of denosumab versus alendronate for aromatase inhibitor-associated osteoporosis in postmenopausal breast cancer patients: a retrospective analysis. [PDF]

BMC Musculoskelet Disord
Zhang Y, Cui W, Hou L.
europepmc   +1 more source

Chronic kidney disease and denosumab in metastatic bone disease: A multicenter Turkish cohort study on severe hypocalcemia, skeletal events, and survival. [PDF]

J Bone Oncol
Ellez Hİ, Semiz HS, Ekinci F, Erdoğan AP, Kuş F, Karataş F, Bayram E, Karaboyun K, Çınkır HY, Yıldırım N, Eryılmaz MK, Bekmez ET, Alan Ö, Özçelik M, Düzköprü Y, Şakalar T, Ak N, İlhan Y, Yavuzşen T, Turhal NS.   +19 more
europepmc   +1 more source